APLASTIC ANEMIA
|
ALTERNATE NAMES
|
Acquired Aplastic Anemia; Anemia Aplastic; Bone Marrow Failure; Idiopathic Aplastic
Anemia; Secondary Aplastic Anemia; Severe Aplastic Anemia
|
DESCRIPTION
|
Aplastic Anemia (AA) is a rare blood disorder that occurs when the body’s bone marrow does not make enough
new cells to replenish blood cells. Although anemia usually refers to low red blood
cell counts, typically in AA there are also low white blood cell and low platelet
counts. In most cases, AA is considered to be idiopathic, meaning the cause is unknown.
Less commonly, AA can be caused by exposure to certain drugs, viral infections (i.e.
hepatitis, Epstein-Barr virus, cytomegalovirus, parvovirus B19, and HIV), autoimmune
disorders (i.e. lupus and rheumatoid arthritis) radiation therapy, or toxins (i.e.
pesticides, benzene or arsenic).
|
DIAGNOSTIC TESTING, PHYSICAL FINDINGS, AND
ICD-9-CM/ICD-10-CM
CODING
|
Diagnostic testing: Bone marrow aspirate and biopsy is required for diagnosis and to rule out other causes
of pancytopenia such as cancer or infection; blood counts documenting anemia, thrombocytopenia,
leukopenia and low reticulocytes counts.
Physical findings:
-
•
Anemia with fatigue and pallor;
-
-
•
Petechiae (non-raised hemorrhage in the skin or in a membrane);
-
-
•
Bleeding of internal organs;
-
•
Frequent or severe infections;
-
-
-
-
•
Shortness of breath during physical activity; and
-
ICD-9:
284.9
ICD-10: D61.3
|
PROGRESSION
|
AA usually gets worse unless the cause is removed or the disease is treated. Mild
and moderate forms of the disease often progress slower than the severe form.
|
TREATMENT
|
Supportive treatments for AA include blood transfusions, platelet transfusions, and
medications such as antithymocyte globulin (ATG) or antilymphocyte globulin (ALG),
cyclosporine, or low dose chemotherapy. If the bone marrow does not recover and start
producing blood cell elements, then bone marrow transplant (BMT) is required. BMT
has been successful in the treatment of young patients, with a long-term survival
of approximately 80%. Older patients have a survival rate of 40 – 70% after a transplant.
If left untreated, severe aplastic anemia can become life threatening.
|
SUGGESTED PROGRAMMATIC
ASSESSMENT* |
Suggested MER for Evaluation:
-
•
Clinical history and examination that describes the diagnostic features and physical
findings;
-
•
Laboratory studies and bone marrow biopsy pathology reports; and
-
•
Documentation of bone marrow or stem cell transplantation.
|
Suggested Listings for Evaluation:
|
DETERMINATION
|
LISTING
|
REMARKS
|
Meets
|
7.17
|
Listing level severity requires documentation of bone marrow or stem cell transplantation;
reevaluate 1 year after transplantation.
|
107.17
|
|
Equals
|
7.17
|
|
107.17
|
|
* Adjudicators may, at their discretion, use the Medical Evidence of Record or the
listings suggested to evaluate the claim. However, the decision to allow or deny the
claim rests with the adjudicator.
|